Hyperbaric Oxygen Therapy for Ulcerative Colitis
- Hyperbaric Oxygen Therapy
- Limited to 30 patients
- 1 Location
This study is evaluating the treatment of ulcerative colitis with hyperbaric oxygen therapy. Recent small studies have shown hyperbaric oxygen can treat ulcerative colitis however researchers don't understand how it does it. This study will look at markers in the body to determine how hyperbaric oxygen treats ulcerative colitis.
You may be eligible to participate if you meet the following criteria:
- Ages 19 and older
- Diagnosed with ulcerative colitis
- In the hospital due to active ulcerative colitis (i.e. not in remission)
How You Can Participate
This study is currently accepting candidates. You would receive medical care from Dr. Corey Siegel at Dartmouth-Hitchcock Medical Center. Answer a few questions to see if you can participate ›
Frequently Asked Questions
- How much does it cost?
- The treatment and doctor visits are free.
- Are traveling expenses covered?
- Travel expenses will generally be covered.
Here's a timeline of what you can expect:
Step 1: Online Pre-screener
Find out if you are a match by answering a few online questions.
Check Your Eligibility ›
Step 2: Phone Call with Care Coordinator
Speak with our Care Team specialist to confirm your candidacy.
Step 3: Screening Appointment
If you are eligible to continue, you will be given an appointment date and time to come to the clinic for a screening visit.
Other Emerging Treatments
Etrolizumab for Ulcerative Colitis (TNF Inhibitors Naive)
This study is evaluating how safe and effective etrolizumab is compared to placebo for the treatment of moderate to severe ulcerative colitis. Participants must have not tried an anti-TNF therapy (e.g. Remicade, Humira, etc.).
Etrolizumab for Ulcerative Colitis (For patients who have previously used anti-TNFs)
This study is evaluating how safe and effective etrolizumab is compared to placebo for the treatment of moderate to severe ulcerative colitis. Participants must have failed an anti-TNF therapy (e.g. Remicade, Humira, etc.) previously.
Vedolizumab for Pouchitis
Vedolizumab is an intraveneous medication for ulcerative colitis who have had bowel surgery involving a proctocolectomy and ileal pouch anal anastomosis.